Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells To Treat Eye Disease
Advanced Cell Technology, Inc. (OTCBB:ACTC) announced that it filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD).
Related News:
Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye …
Advanced Cell Technology files an IND with the FDA for study using embryonic stem cells to treat SMD
Advanced Cell Technology Files IND With FDA For First Clinical Trial Using Embryonic Stem Cells To Treat …